Telomir Pharmaceuticals (NASDAQ:TELO) Trading 1.5% Higher – Here’s Why

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) traded up 1.5% during trading on Monday . The company traded as high as $1.36 and last traded at $1.34. 54,096 shares were traded during mid-day trading, a decline of 34% from the average session volume of 81,803 shares. The stock had previously closed at $1.32.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, January 22nd. Rodman & Renshaw started coverage on Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating on the stock. Finally, Wall Street Zen raised Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Price Performance

The stock has a market capitalization of $46.07 million, a price-to-earnings ratio of -3.62 and a beta of -0.66. The firm’s fifty day moving average is $1.27 and its 200-day moving average is $1.36.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of institutional investors have recently modified their holdings of TELO. Geode Capital Management LLC lifted its position in shares of Telomir Pharmaceuticals by 14.0% during the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock worth $297,000 after purchasing an additional 27,519 shares during the last quarter. Marshall Wace LLP acquired a new position in Telomir Pharmaceuticals in the second quarter worth about $95,000. Raymond James Financial Inc. increased its holdings in Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after buying an additional 73,547 shares during the last quarter. Jane Street Group LLC acquired a new stake in Telomir Pharmaceuticals during the second quarter valued at approximately $62,000. Finally, XTX Topco Ltd acquired a new stake in Telomir Pharmaceuticals during the fourth quarter valued at approximately $53,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.